Mason Carrico
Stock Analyst at Stephens & Co.
(2.05)
# 3,032
Out of 4,969 analysts
73
Total ratings
35.38%
Success rate
-1.8%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $8.70 | +26.51% | 2 | Sep 2, 2025 | |
| NTRA Natera | Reiterates: Overweight | $183 | $169.34 | +8.07% | 5 | Aug 15, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $34.25 | +95.62% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $96.98 | +8.27% | 8 | May 20, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $1.8 | $1.27 | +41.73% | 5 | May 15, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $13.39 | +4.56% | 6 | May 15, 2025 | |
| HOLX Hologic | Maintains: Overweight | $77 → $70 | $66.62 | +5.08% | 4 | May 13, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $14.01 | +185.51% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $93.95 | +22.41% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $30.12 | +49.40% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $66.26 | -16.99% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.06 | +47.78% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $27.60 | -38.41% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $40.20 | +29.35% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $6.93 | +188.60% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $24.26 | +69.00% | 7 | Jan 2, 2025 |
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $8.70
Upside: +26.51%
Natera
Aug 15, 2025
Reiterates: Overweight
Price Target: $183
Current: $169.34
Upside: +8.07%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $34.25
Upside: +95.62%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $96.98
Upside: +8.27%
Pacific Biosciences of California
May 15, 2025
Reiterates: Overweight
Price Target: $1.8
Current: $1.27
Upside: +41.73%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $13.39
Upside: +4.56%
Hologic
May 13, 2025
Maintains: Overweight
Price Target: $77 → $70
Current: $66.62
Upside: +5.08%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $14.01
Upside: +185.51%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $93.95
Upside: +22.41%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $30.12
Upside: +49.40%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $66.26
Upside: -16.99%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.06
Upside: +47.78%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $27.60
Upside: -38.41%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $40.20
Upside: +29.35%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $6.93
Upside: +188.60%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $24.26
Upside: +69.00%